Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
08 août 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
Patients dosed with ulixacaltamide up to 14 weeks showed maintained or improved efficacy results, as measured by mean changes in the modified Activities of Daily Living 11 (mADL111) Patients...
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
07 août 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
Composite qEEG measure showed change from placebo after first dose of 5 mg Effect in the composite qEEG measured through 10-day treatment period Ongoing PRAX-628 Phase 2 Photo-Paroxysmal...
Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
03 août 2023 16h12 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
22 juin 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into Q1 2025 Phase 2 Photoparoxsymal Response (PPR) study to...
Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering
15 juin 2023 23h58 HE
|
Praxis Precision Medicines, Inc.
BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
15 juin 2023 16h01 HE
|
Praxis Precision Medicines, Inc.
BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...
Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
09 juin 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
Phase 3 program to include one parallel group study and one randomized withdrawal study mADL11 as primary endpoint Single 60 mg/day dose to be tested BOSTON, June 09, 2023 ...
Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
02 juin 2023 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
11 mai 2023 07h30 HE
|
Praxis Precision Medicines, Inc.
Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023 PRAX-628 Phase 1 study results support preclinical profile indicating potential for best-in-class-efficacy for...
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
11 mai 2023 06h55 HE
|
Praxis Precision Medicines, Inc.
PRAX-628 demonstrated a favorable safety and tolerability profile in healthy volunteers at concentrations more than 15-fold the MES EC50; PRAX-628 predicted therapeutic range at least 3-fold wider...